Alkermes to Report Third Quarter Financial Results on October 24, 2024

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced it will host a conference call and webcast presentation on Thursday, October 24, 2024, at 8:00 a.m. ET to discuss its third quarter financial results. The event will be accessible via the Investors section of Alkermes' website, with a webcast player and accompanying slides available. Participants can join the conference call by dialing +1 877 407 2988 (U.S. callers) or +1 201 389 0923 (international callers).

Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company has a portfolio of proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Additionally, Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia.

Positive

• Alkermes has a diverse portfolio of commercial products for various mental health conditions
• The company has a pipeline of clinical and preclinical candidates for neurological disorders

Negative

• None.

DUBLIN, Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, Oct. 24, 2024 to discuss the company's third quarter financial results.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. 

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-third-quarter-financial-results-on-october-24-2024-302279558.html

SOURCE Alkermes plc

FAQ

When will Alkermes (ALKS) report its Q3 2024 financial results?

Alkermes (ALKS) will report its third quarter 2024 financial results on Thursday, October 24, 2024.

How can investors access Alkermes' (ALKS) Q3 2024 earnings call?

Investors can access Alkermes' Q3 2024 earnings call via a webcast on the company's website or by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers.

What are the main therapeutic areas Alkermes (ALKS) focuses on?

Alkermes focuses on neuroscience, with products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and a pipeline for neurological disorders like narcolepsy and idiopathic hypersomnia.